Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | FHIT | P49789 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28293724 | 0.83 | LMNA (0.50) | ALDH1A1MAPTSMN1; SMN2HPGDKDM4E | |
| SCHEMBL128677 | 0.81 | CDC7 (0.46) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL16933028 | 0.80 | CDC7 (0.60) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL13260686 | 0.79 | MAPK1 (0.43) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL19134612 | 0.79 | CDC7 (0.49) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL12184418 | 0.79 | SMN1; SMN2 (0.49) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL3300624 | 0.79 | KDM4E (0.48) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL1641657 | 0.79 | CDC7 (0.44) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL128676 | 0.79 | CDC7 (0.48) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL10272646 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024536-B | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2022-05-27 | — | — | CN | claimed |
| CN-113024536-A | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2021-06-25 | — | — | CN | claimed |
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220273669-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP DOHME CORP. (US) | 2022-09-01 | — | — | US | disclosed |
| CN-113024536-B | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-113024536-A | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2021-06-25 | — | — | CN | disclosed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | NPR1, NPPA, NPR3 | ALDH1A1 2115/4885MAPT 4803/4885SMN1; SMN2 2593/4885 |
| US-20220273669-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | NPR1, NPPA, NPR3 | ALDH1A1 2309/4885MAPT 4796/4885SMN1; SMN2 2660/4885 |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ABL1, ABL2, SRC | ALDH1A1 1770/4885MAPT 3035/4885SMN1; SMN2 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.